早期乳腺癌的组织病理特征:比较分析
Iraj Feizi1, Khatereh Isazadehfar2, Farshid Sadegzadeh3
1Department of Surgery, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
The international tinnitus journal
|March 20, 2024
概括
在被诊断为乳腺癌的年轻女性中,淋巴结参与率更高. 这表明,诊断时的早期年龄与更差的预后有关,即使瘤阶段化类似.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 妇女健康 妇女健康
背景情况:
- 乳腺癌是女性普遍存在的恶性瘤,早期诊断往往与更糟糕的预后相关.
- 导致年轻乳腺癌患者结果较差的因素包括疾病晚期和延迟呈现.
- 现有研究提出了各种各样的发现,需要进一步调查与年龄相关的遗传病理差异.
研究的目的:
- 在40岁以下和40岁以上的女性中调查和比较乳腺癌组织病理学.
- 在乳腺癌患者中分析状淋巴结参与的年龄特异性差异.
主要方法:
- 一项涉及64名乳腺癌患者的横截面研究,这些患者在2014年至2015年期间被诊断为乳腺癌.
- 从患者记录中收集了组织病理学数据.
- 评估和比较两个年龄组 (40岁以下和40岁以上) 与相似的瘤 (T) 阶段.
主要成果:
- 该研究包括64名患者,71.9%的患者40岁以上,28.1%的患者40岁以下.
- 侵入性导管癌是最常见的瘤类型.
- 在40岁以下的患者中,与40岁以上的患者相比,即使在相当的瘤阶段 (T=1,T=2) 中,也观察到显著更高的状淋巴结参与率.
结论:
- 40岁以下患有乳腺癌的患者在相似的瘤阶段表现出较高的下淋巴结转移率.
- 这一发现支持早期乳腺癌与更具侵略性的疾病过程之间的关联,表明预后更差.
- 年龄是影响乳腺癌进展和结果的关键因素.
更多相关视频
11:47Time-lapse Imaging of Primary Preneoplastic Mammary Epithelial Cells Derived from Genetically Engineered Mouse Models of Breast Cancer
Published on: February 8, 2013
11.9K
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.6K
相关概念视频
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345